# A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

> **NCT05630677** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 21 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** AZD5055 solution for infusion
- **DRUG:** AZD5055 oral suspension
- **DRUG:** AZD5055 film-coated tablet
- **DRUG:** AZD5055 film-coated tablet
- **DRUG:** Rabeprazole, Delayed-release tablet
- **DRUG:** Rabeprazole, Delayed-release tablet

## Key facts

- **NCT ID:** NCT05630677
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-04
- **Primary completion:** 2023-02-09
- **Final completion:** 2023-02-09
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05630677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05630677, "A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05630677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*